KR102752259B1 - 인자 h 결합 단백질 변이체 및 이의 사용 방법 - Google Patents

인자 h 결합 단백질 변이체 및 이의 사용 방법 Download PDF

Info

Publication number
KR102752259B1
KR102752259B1 KR1020177004378A KR20177004378A KR102752259B1 KR 102752259 B1 KR102752259 B1 KR 102752259B1 KR 1020177004378 A KR1020177004378 A KR 1020177004378A KR 20177004378 A KR20177004378 A KR 20177004378A KR 102752259 B1 KR102752259 B1 KR 102752259B1
Authority
KR
South Korea
Prior art keywords
fhbp
gly
amino acid
variant
ala
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
KR1020177004378A
Other languages
English (en)
Korean (ko)
Other versions
KR20170028442A (ko
Inventor
피터 티. 비어닝크
Original Assignee
칠드런즈 하스피틀 앤드 리써치 센터 앳 오클랜드
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 칠드런즈 하스피틀 앤드 리써치 센터 앳 오클랜드 filed Critical 칠드런즈 하스피틀 앤드 리써치 센터 앳 오클랜드
Priority to KR1020237036853A priority Critical patent/KR102761870B1/ko
Publication of KR20170028442A publication Critical patent/KR20170028442A/ko
Application granted granted Critical
Publication of KR102752259B1 publication Critical patent/KR102752259B1/ko
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/095—Neisseria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/22—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Neisseriaceae (F)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55505—Inorganic adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A61K2039/575—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 humoral response

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Genetics & Genomics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
KR1020177004378A 2014-07-23 2015-07-22 인자 h 결합 단백질 변이체 및 이의 사용 방법 Active KR102752259B1 (ko)

Priority Applications (1)

Application Number Priority Date Filing Date Title
KR1020237036853A KR102761870B1 (ko) 2014-07-23 2015-07-22 인자 h 결합 단백질 변이체 및 이의 사용 방법

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201462028123P 2014-07-23 2014-07-23
US62/028,123 2014-07-23
PCT/US2015/041616 WO2016014719A1 (en) 2014-07-23 2015-07-22 Factor h binding protein variants and methods of use thereof

Related Child Applications (1)

Application Number Title Priority Date Filing Date
KR1020237036853A Division KR102761870B1 (ko) 2014-07-23 2015-07-22 인자 h 결합 단백질 변이체 및 이의 사용 방법

Publications (2)

Publication Number Publication Date
KR20170028442A KR20170028442A (ko) 2017-03-13
KR102752259B1 true KR102752259B1 (ko) 2025-01-13

Family

ID=55163727

Family Applications (2)

Application Number Title Priority Date Filing Date
KR1020177004378A Active KR102752259B1 (ko) 2014-07-23 2015-07-22 인자 h 결합 단백질 변이체 및 이의 사용 방법
KR1020237036853A Active KR102761870B1 (ko) 2014-07-23 2015-07-22 인자 h 결합 단백질 변이체 및 이의 사용 방법

Family Applications After (1)

Application Number Title Priority Date Filing Date
KR1020237036853A Active KR102761870B1 (ko) 2014-07-23 2015-07-22 인자 h 결합 단백질 변이체 및 이의 사용 방법

Country Status (15)

Country Link
US (10) US10266572B2 (cg-RX-API-DMAC7.html)
EP (2) EP3172224B1 (cg-RX-API-DMAC7.html)
JP (4) JP6796057B2 (cg-RX-API-DMAC7.html)
KR (2) KR102752259B1 (cg-RX-API-DMAC7.html)
CN (3) CN106715464B (cg-RX-API-DMAC7.html)
AU (5) AU2015292615B2 (cg-RX-API-DMAC7.html)
BR (1) BR112017001417B1 (cg-RX-API-DMAC7.html)
CA (2) CA3212723A1 (cg-RX-API-DMAC7.html)
CO (1) CO2017000558A2 (cg-RX-API-DMAC7.html)
CR (1) CR20170020A (cg-RX-API-DMAC7.html)
ES (1) ES2922554T3 (cg-RX-API-DMAC7.html)
MX (3) MX382409B (cg-RX-API-DMAC7.html)
NZ (2) NZ729206A (cg-RX-API-DMAC7.html)
RU (1) RU2714248C2 (cg-RX-API-DMAC7.html)
WO (1) WO2016014719A1 (cg-RX-API-DMAC7.html)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2661569T3 (es) 2010-03-30 2018-04-02 Children's Hospital & Research Center At Oakland Proteínas de unión al factor H (fHbp) con propiedades alteradas y métodos de uso de las mismas
ES2922554T3 (es) 2014-07-23 2022-09-16 Childrens Hospital & Res Center At Oakland Variantes de proteínas de unión al factor H y métodos de uso de las mismas
GB201614687D0 (en) * 2016-08-31 2016-10-12 Univ Oxford Innovation Ltd fHbp scaffold
WO2018093176A2 (ko) 2016-11-16 2018-05-24 주식회사 케이엠더블유 적층구조의 mimo 안테나 어셈블리
KR101854309B1 (ko) 2016-11-16 2018-05-03 주식회사 케이엠더블유 Mimo 안테나 어셈블리
US11542467B2 (en) * 2017-12-04 2023-01-03 Intravacc B.V. Process for producing outer membrane vesicles
EP3607967A1 (en) 2018-08-09 2020-02-12 GlaxoSmithKline Biologicals S.A. Modified meningococcal fhbp polypeptides
GB202016604D0 (en) 2020-10-20 2020-12-02 Univ Of Oxford Compositions and methods for inducing an immune response
TW202245836A (zh) 2021-02-19 2022-12-01 美商賽諾菲巴斯德公司 重組ｂ型腦膜炎球菌疫苗
TW202423477A (zh) 2022-08-03 2024-06-16 美商賽諾菲巴斯德公司 針對腦膜炎奈瑟氏菌b的含佐劑免疫原性組成物

Citations (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060251670A1 (en) 2002-11-22 2006-11-09 Maurizio Comanducci Multiple variants of meningococcal protein nmb1870
US20060257413A1 (en) 2001-10-11 2006-11-16 Zlotnick Gary W Novel immunogenic compositions for the prevention and treatment of meningococcal disease
US20070031449A1 (en) 2003-12-23 2007-02-08 Bos Martine P Vaccine
US20110256180A1 (en) * 2010-03-30 2011-10-20 Beernink Peter T Factor H Binding Proteins (FHBP) with Altered Properties and Methods of Use Thereof
US20110318378A1 (en) 2008-09-03 2011-12-29 Peter Beernink Peptides Presenting an Epitope of a Domain of Factor H Binding Protein and Methods of Use
US20120052092A1 (en) 2008-10-25 2012-03-01 Imperial Innovations Limited Vaccine compositions comprising a mutated factor h binding protein
US20120093867A1 (en) 2005-01-27 2012-04-19 Granoff Dan M GNA1870-Based Vesicle Vaccines for Broad Spectrum Protection Against Diseases Caused by Neisseria Meningitidis
WO2015017817A1 (en) 2013-08-02 2015-02-05 Children's Hospital & Research Center Oakland Non-naturally occurring factor h binding proteins (fhbp) and methods of use thereof

Family Cites Families (58)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4235871A (en) 1978-02-24 1980-11-25 Papahadjopoulos Demetrios P Method of encapsulating biologically active materials in lipid vesicles
US4501728A (en) 1983-01-06 1985-02-26 Technology Unlimited, Inc. Masking of liposomes from RES recognition
US4837028A (en) 1986-12-24 1989-06-06 Liposome Technology, Inc. Liposomes with enhanced circulation time
GB8815795D0 (en) 1988-07-02 1988-08-10 Bkl Extrusions Ltd Glazing bead
HU212924B (en) 1989-05-25 1996-12-30 Chiron Corp Adjuvant formulation comprising a submicron oil droplet emulsion
CA2138997C (en) 1992-06-25 2003-06-03 Jean-Paul Prieels Vaccine composition containing adjuvants
EP0812593B8 (en) 1993-03-23 2010-11-10 SmithKline Beecham Biologicals S.A. Vaccine compositions containing 3-0 deacylated monophosphoryl lipid a
GB9326253D0 (en) 1993-12-23 1994-02-23 Smithkline Beecham Biolog Vaccines
IL117483A (en) 1995-03-17 2008-03-20 Bernard Brodeur MENINGITIDIS NEISSERIA shell protein is resistant to proteinase K.
GB9513261D0 (en) 1995-06-29 1995-09-06 Smithkline Beecham Biolog Vaccines
US6339068B1 (en) 1997-05-20 2002-01-15 University Of Iowa Research Foundation Vectors and methods for immunization or therapeutic protocols
GB9712347D0 (en) 1997-06-14 1997-08-13 Smithkline Beecham Biolog Vaccine
EP1279401B1 (en) 1997-09-05 2008-01-09 GlaxoSmithKline Biologicals S.A. Oil in water emulsions containing saponins
US6303114B1 (en) 1998-03-05 2001-10-16 The Medical College Of Ohio IL-12 enhancement of immune responses to T-independent antigens
TR200002930T2 (tr) 1998-04-09 2000-12-21 Smithkline Beecham Biologicals S.A. Kolaylaştırıcı kompozisyonlar
US20070026021A1 (en) 1998-05-01 2007-02-01 Chiron S.R.I. Neisseria meningitidis antigens and compositions
MX343752B (es) 1998-05-01 2016-11-22 Novartis Vaccines & Diagnostics Inc Antigenos de neisseria meningitidis y composiciones que los contienen.
GB9817052D0 (en) 1998-08-05 1998-09-30 Smithkline Beecham Biolog Vaccine
US7357936B1 (en) 1998-10-16 2008-04-15 Smithkline Beecham Biologicals, Sa Adjuvant systems and vaccines
EP1162999B1 (en) 1999-03-19 2006-11-29 Glaxosmithkline Biologicals S.A. Vaccine against Streptococcus pneumoniae
WO2000062800A2 (en) 1999-04-19 2000-10-26 Smithkline Beecham Biologicals Sa Adjuvant composition comprising saponin and an immunostimulatory oligonucleotide
IL148672A0 (en) 1999-09-24 2002-09-12 Smithkline Beecham Biolog Use of combination of polyxyethylene sorbitan ester and octoxynol as adjuvant and its use in vaccines
AU766635B2 (en) 1999-09-24 2003-10-23 Smithkline Beecham Biologicals (Sa) Adjuvant comprising a polyxyethylene alkyl ether or ester and at least one nonionic surfactant
AU1917501A (en) 1999-11-12 2001-06-06 University Of Iowa Research Foundation, The Control of neisserial membrane synthesis
AU2013206190A1 (en) 1999-11-29 2013-06-27 Novartis Vaccines And Diagnostics S.R.L. Compositions comprising Neisseria meningitidis antigens from serogroups B and C as well as a further antigen
NZ520466A (en) 2000-01-17 2003-09-26 Chiron S Outer membrane vesicle (OMV) vaccine comprising n. meningitidis serogroup B outer membrane proteins
ATE503837T1 (de) 2000-02-28 2011-04-15 Novartis Vaccines & Diagnostic Hybride expression neisserscher proteine
GB0103170D0 (en) 2001-02-08 2001-03-28 Smithkline Beecham Biolog Vaccine composition
US6839862B2 (en) 2001-05-31 2005-01-04 Koninklijke Philips Electronics N.V. Parallel data communication having skew intolerant data groups
GB0121591D0 (en) 2001-09-06 2001-10-24 Chiron Spa Hybrid and tandem expression of neisserial proteins
US7785608B2 (en) 2002-08-30 2010-08-31 Wyeth Holdings Corporation Immunogenic compositions for the prevention and treatment of meningococcal disease
ATE492288T1 (de) * 2002-10-11 2011-01-15 Novartis Vaccines & Diagnostic Polypeptidimpstoffe zum breiten schutz gegen hypervirulente meningokokken-linien
WO2004074433A2 (en) 2003-01-30 2004-09-02 Yale University Rag polypeptides, nucleic acids, and their use
GB0408977D0 (en) * 2004-04-22 2004-05-26 Chiron Srl Immunising against meningococcal serogroup Y using proteins
GB0419408D0 (en) 2004-09-01 2004-10-06 Chiron Srl 741 chimeric polypeptides
CN101160412A (zh) 2005-02-14 2008-04-09 爱荷华大学研究基金会 治疗和诊断年龄相关性黄斑变性的方法和试剂
GB0510790D0 (en) 2005-05-26 2005-06-29 Syngenta Crop Protection Ag Anti-CD16 binding molecules
GB0524066D0 (en) 2005-11-25 2006-01-04 Chiron Srl 741 ii
WO2009038889A1 (en) 2007-08-02 2009-03-26 Children's Hospital And Research Center At Oakland Fhbp- and lpxl1-based vesicle vaccines for broad spectrum protection against diseases caused by neisseria meningitidis
US9579372B2 (en) * 2008-02-21 2017-02-28 Glaxosmithkline Biologicals Sa Meningococcal fHBP polypeptides
EP2631245A1 (en) 2008-03-10 2013-08-28 Children's Hospital & Research Center at Oakland Chimeric factor H binding proteins (fHBP) containing a heterologous B domain and methods of use
US8476032B2 (en) 2008-08-27 2013-07-02 Children's Hospital & Research Center Oakland Complement factor H-based assays for serum bactericidal activity against Neisseria meningitidis
IT1394288B1 (it) 2008-09-12 2012-06-06 Novartis Vaccines & Diagnostic Immunogeni di proteine che legano il fattore h.
HRP20201076T1 (hr) 2009-03-24 2020-10-30 Glaxosmithkline Biologicals Sa Adjuvantni vezujući protein meningokokalnog faktora h
WO2010127172A2 (en) 2009-04-30 2010-11-04 Children's Hospital & Research Center At Oakland Chimeric factor h binding proteins (fhbp) and methods of use
AU2010310985B2 (en) * 2009-10-27 2014-11-06 Glaxosmithkline Biologicals S.A. Modified meningococcal fHBP polypeptides
CA2809758C (en) * 2010-09-10 2021-07-13 Wyeth Llc Non-lipidated variants of neisseria meningitidis orf2086 antigens
CN102028941B (zh) 2011-02-11 2013-02-13 中国医学科学院医学生物学研究所 一种b群脑膜炎球菌重组蛋白嵌合疫苗及其制备方法
US9272006B2 (en) 2011-07-07 2016-03-01 De Staat Der Nederlanden, Vert. Door De Minister Van Vws Ministerie Van Volksgezondheid, Welzijn En Sport Process for detergent-free production of outer membrane vesicles of a gram-negative bacterium
WO2013078223A1 (en) 2011-11-23 2013-05-30 Children's Hospital & Research Center Oakland Anti-factor h binding protein antibodies and methods of use thereof
MX351993B (es) * 2012-03-09 2017-11-03 Pfizer Composiciones de neisseria meningitidis y metodos de las mismas.
GB201215005D0 (en) 2012-08-23 2012-10-10 Isis Innovation Stabilised meningitis vaccine
SG10201907875TA (en) 2014-02-28 2019-09-27 Glaxosmithkline Biologicals Sa Modified meningococcal fhbp polypeptides
KR20150128099A (ko) 2014-05-08 2015-11-18 (주)엘지하우시스 Pla 및 pha 혼합수지를 이용한 벽지 및 그 제조 방법
CN107349423B (zh) * 2014-06-24 2021-03-19 上海生物制品研究所有限责任公司 一种脑膜炎球菌抗原组合及其应用
AR102324A1 (es) * 2014-07-17 2017-02-22 Glaxosmithkline Biologicals Sa Polipéptidos fhbp (proteína de unión al factor h) meningocócicos modificados
ES2922554T3 (es) 2014-07-23 2022-09-16 Childrens Hospital & Res Center At Oakland Variantes de proteínas de unión al factor H y métodos de uso de las mismas
EP3607967A1 (en) * 2018-08-09 2020-02-12 GlaxoSmithKline Biologicals S.A. Modified meningococcal fhbp polypeptides

Patent Citations (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060257413A1 (en) 2001-10-11 2006-11-16 Zlotnick Gary W Novel immunogenic compositions for the prevention and treatment of meningococcal disease
US20060251670A1 (en) 2002-11-22 2006-11-09 Maurizio Comanducci Multiple variants of meningococcal protein nmb1870
US20070031449A1 (en) 2003-12-23 2007-02-08 Bos Martine P Vaccine
US20120093867A1 (en) 2005-01-27 2012-04-19 Granoff Dan M GNA1870-Based Vesicle Vaccines for Broad Spectrum Protection Against Diseases Caused by Neisseria Meningitidis
US20110318378A1 (en) 2008-09-03 2011-12-29 Peter Beernink Peptides Presenting an Epitope of a Domain of Factor H Binding Protein and Methods of Use
US20120052092A1 (en) 2008-10-25 2012-03-01 Imperial Innovations Limited Vaccine compositions comprising a mutated factor h binding protein
US20110256180A1 (en) * 2010-03-30 2011-10-20 Beernink Peter T Factor H Binding Proteins (FHBP) with Altered Properties and Methods of Use Thereof
AU2011238670A1 (en) 2010-03-30 2012-09-13 Children's Hospital & Research Center Oakland Factor H binding proteins (FHBP) with altered properties and methods of use thereof
WO2015017817A1 (en) 2013-08-02 2015-02-05 Children's Hospital & Research Center Oakland Non-naturally occurring factor h binding proteins (fhbp) and methods of use thereof

Also Published As

Publication number Publication date
CN106715464B (zh) 2021-03-16
US20250154206A1 (en) 2025-05-15
AU2019264600B2 (en) 2021-04-01
US11673920B2 (en) 2023-06-13
US10266572B2 (en) 2019-04-23
JP2025108722A (ja) 2025-07-23
US20200095288A1 (en) 2020-03-26
US10995122B2 (en) 2021-05-04
CA2955802A1 (en) 2016-01-28
EP4074726A3 (en) 2022-11-23
JP6796057B2 (ja) 2020-12-02
US20240025951A1 (en) 2024-01-25
US10487122B2 (en) 2019-11-26
US12129282B2 (en) 2024-10-29
MX2023000204A (es) 2023-02-09
CA2955802C (en) 2023-10-31
RU2020105192A (ru) 2020-02-12
NZ766003A (en) 2024-01-26
JP2021000121A (ja) 2021-01-07
AU2019264600A1 (en) 2019-12-05
US20210101942A1 (en) 2021-04-08
CO2017000558A2 (es) 2017-06-20
KR20230155595A (ko) 2023-11-10
US20250136648A1 (en) 2025-05-01
NZ766005A (en) 2024-03-22
CN106715464A (zh) 2017-05-24
EP3172224A4 (en) 2018-04-18
KR102761870B1 (ko) 2025-02-05
JP2017522877A (ja) 2017-08-17
WO2016014719A1 (en) 2016-01-28
US11834476B2 (en) 2023-12-05
MX382409B (es) 2025-03-13
CN112851768A (zh) 2021-05-28
CR20170020A (es) 2017-08-10
BR112017001417A2 (pt) 2017-11-21
RU2017104742A (ru) 2018-08-29
US10836799B2 (en) 2020-11-17
AU2023204391A1 (en) 2023-08-03
BR112017001417B1 (pt) 2023-11-07
AU2023204391B2 (en) 2025-01-23
EP3172224B1 (en) 2022-06-29
US20190225655A1 (en) 2019-07-25
EP3172224A1 (en) 2017-05-31
MX2021005373A (es) 2021-07-06
US20200109179A1 (en) 2020-04-09
AU2015292615B2 (en) 2019-10-24
US20240101610A1 (en) 2024-03-28
RU2714248C2 (ru) 2020-02-13
EP4074726A2 (en) 2022-10-19
AU2015292615A1 (en) 2017-03-16
ES2922554T3 (es) 2022-09-16
CA3212723A1 (en) 2016-01-28
NZ766444A (en) 2024-01-26
US20210340191A1 (en) 2021-11-04
CN119613509A (zh) 2025-03-14
JP2023011916A (ja) 2023-01-24
US20170183384A1 (en) 2017-06-29
NZ729206A (en) 2022-07-01
AU2021203828A1 (en) 2021-07-08
JP7719046B2 (ja) 2025-08-05
US12269849B2 (en) 2025-04-08
RU2017104742A3 (cg-RX-API-DMAC7.html) 2019-02-27
KR20170028442A (ko) 2017-03-13
JP7221917B2 (ja) 2023-02-14
MX2017001038A (es) 2018-02-09
AU2025202774A1 (en) 2025-05-08
AU2021203828B2 (en) 2023-04-13

Similar Documents

Publication Publication Date Title
US12269849B2 (en) Factor H binding protein variants and methods of use thereof
HK40076049A (en) Factor h binding protein variants and methods of use thereof
RU2811942C2 (ru) Варианты фактор h-связывающего белка и способы их применения
HK1238266A1 (en) Factor h binding protein variants and methods of use thereof
HK1238266B (en) Factor h binding protein variants and methods of use thereof

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 20170216

Patent event code: PA01051R01D

Comment text: International Patent Application

PG1501 Laying open of application
A201 Request for examination
AMND Amendment
PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 20200720

Comment text: Request for Examination of Application

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20220927

Patent event code: PE09021S01D

AMND Amendment
E601 Decision to refuse application
PE0601 Decision on rejection of patent

Patent event date: 20230314

Comment text: Decision to Refuse Application

Patent event code: PE06012S01D

Patent event date: 20220927

Comment text: Notification of reason for refusal

Patent event code: PE06011S01I

X091 Application refused [patent]
AMND Amendment
PX0901 Re-examination

Patent event code: PX09011S01I

Patent event date: 20230314

Comment text: Decision to Refuse Application

Patent event code: PX09012R01I

Patent event date: 20221221

Comment text: Amendment to Specification, etc.

Patent event code: PX09012R01I

Patent event date: 20200720

Comment text: Amendment to Specification, etc.

PX0601 Decision of rejection after re-examination

Comment text: Decision to Refuse Application

Patent event code: PX06014S01D

Patent event date: 20230726

Comment text: Amendment to Specification, etc.

Patent event code: PX06012R01I

Patent event date: 20230612

Comment text: Decision to Refuse Application

Patent event code: PX06011S01I

Patent event date: 20230314

Comment text: Amendment to Specification, etc.

Patent event code: PX06012R01I

Patent event date: 20221221

Comment text: Notification of reason for refusal

Patent event code: PX06013S01I

Patent event date: 20220927

Comment text: Amendment to Specification, etc.

Patent event code: PX06012R01I

Patent event date: 20200720

X601 Decision of rejection after re-examination
J201 Request for trial against refusal decision
PJ0201 Trial against decision of rejection

Patent event date: 20231026

Comment text: Request for Trial against Decision on Refusal

Patent event code: PJ02012R01D

Patent event date: 20230726

Comment text: Decision to Refuse Application

Patent event code: PJ02011S01I

Patent event date: 20230314

Comment text: Decision to Refuse Application

Patent event code: PJ02011S01I

Appeal kind category: Appeal against decision to decline refusal

Appeal identifier: 2023101002291

Request date: 20231026

J301 Trial decision

Free format text: TRIAL NUMBER: 2023101002291; TRIAL DECISION FOR APPEAL AGAINST DECISION TO DECLINE REFUSAL REQUESTED 20231026

Effective date: 20241014

PJ1301 Trial decision

Patent event code: PJ13011S01D

Patent event date: 20241014

Comment text: Trial Decision on Objection to Decision on Refusal

Appeal kind category: Appeal against decision to decline refusal

Request date: 20231026

Decision date: 20241014

Appeal identifier: 2023101002291

PS0901 Examination by remand of revocation

Patent event code: PS09011S01I

Patent event date: 20241015

Comment text: Notice of Trial Decision (Remand of Revocation)

S901 Examination by remand of revocation
GRNO Decision to grant (after opposition)
PS0701 Decision of registration after remand of revocation

Patent event date: 20241023

Patent event code: PS07012S01D

Comment text: Decision to Grant Registration

GRNT Written decision to grant
PR0701 Registration of establishment

Comment text: Registration of Establishment

Patent event date: 20250106

Patent event code: PR07011E01D

PR1002 Payment of registration fee

Payment date: 20250107

End annual number: 3

Start annual number: 1

PG1601 Publication of registration